Moleculin Strengthens Global Intellectual Property Portfolio Around Annamycin, Secures Korean Patent Allowance
Nov 18, 2026, 9:49 AM EST1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The Korean patent allowance strengthens Moleculin’s geographic IP exclusivity for Annamycin and reduces competitor freedom-to-operate risk in a key Asia-Pacific market; the effect is primarily on legal exclusivity and potential partnering/licensing leverage rather than immediate revenue.
AI summary
What happened, with direct paths to the underlying reporting
South Korea has granted Moleculin a patent (application No. 10-2022-7000486) covering a method of reconstituting liposomal Annamycin, adding Korea to its multi-jurisdictional IP estate that the company says spans 20+ jurisdictions.
South Korea’s Ministry of Intellectual Property issued a decision to grant a patent covering the Company’s method of reconstituting liposomal Annamycin.
The Korean allowance corresponds to patent application No. 10-2022-7000486 titled, “Method of Reconstituting Liposomal Annamycin.”
Moleculin says the allowance joins existing granted/allowed reconstitution patents in jurisdictions including the United States, Australia, Canada, China, Europe, Israel, Japan, Mexico, Singapore and Taiwan.
The company states its overall Annamycin portfolio now spans more than 20 jurisdictions across North America, Europe and Asia-Pacific.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event